This report analyzes global medicine spending and usage patterns and projects trends through 2025, incorporating the effects of COVID-19. It forecasts global medicine spending growth of 3–6% annually, driven by innovation and specialty medicines, while offset by patent expiries and biosimilars. Oncology and immunology are expected to lead growth, with specialty medicines comprising nearly 60% of spending in developed markets. The report highlights temporary pandemic-related disruptions, long-term shifts in patient behavior, and widening differences between developed and pharmerging markets. It emphasizes the need to balance access, affordability, and innovation amid ongoing healthcare system pressures.

Join for free to read